Bayer

This study is tracking 480 people with neovascular glaucoma, a serious eye condition, who are receiving the drug Eylea (aflibercept) as part of their normal care. Researchers are monitoring side effects and how well the drug controls eye pressure and vision over 6 months. The goa…

This early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, so…

This study tests an experimental drug called BAY 3401016 in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that damages kidneys, hearing, and eyes. The drug works by blocking a protein thought to cause kidney injury, with the goal of slowing the loss of ki…

This study tests a new oral drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific EGFR or HER2 mutations. The trial has four parts to find the safest dose and see if the drug shrinks tumors. About 400 participants will take the drug daily until …

This study tests whether switching from tafamidis to acoramidis can raise blood levels of transthyretin (TTR) in adults with transthyretin amyloid cardiomyopathy (ATTR-CM). The drug acoramidis stabilizes TTR to prevent harmful amyloid clumps that stiffen the heart. Researchers wi…

This study tests the long-term safety of finerenone, a medicine that may help the heart pump better by reducing inflammation and scarring. It is for children from birth to 18 years old with heart failure and a weak left ventricle. All participants will take finerenone along with …

This study tests the long-term safety of finerenone, a drug that helps control a key system involved in kidney damage, in children aged 1 to 18 with chronic kidney disease and proteinuria. All 100 participants will take finerenone alongside their usual ACE inhibitor or ARB medica…

This study tests a new drug, BAY 3713372, for people with solid tumors that have a specific genetic deletion called MTAP. The drug is designed to kill cancer cells while sparing normal cells. The trial will first find a safe dose, then test how well it works in up to 450 particip…

This early study tests a new drug called BAY 3389934 in 36 hospital ICU patients with sepsis-induced coagulopathy, a condition where the body forms dangerous blood clots. The main goal is to check safety and find the right dose. Researchers will monitor side effects and blood clo…

This study tests whether the Mirena IUD, a birth control device that releases hormones, can reverse a noncancerous thickening of the uterine lining better than daily hormone pills. About 207 women with nonatypical endometrial hyperplasia will be randomly assigned to get either Mi…

This study tests whether taking darolutamide (a hormone-blocking pill) plus standard hormone therapy for 12 or 24 weeks before prostate removal surgery can reduce or eliminate cancer in men with high-risk localized prostate cancer. About 250 men in China will be randomly assigned…

This early-phase study tests a new experimental drug, BAY 3498264, combined with the approved cancer drug sotorasib in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see if the combination can make sotorasib work lon…

This study tests whether adding finerenone to standard blood pressure medicines can reduce protein in the urine of children with chronic kidney disease. About 219 children aged 6 months to under 18 years will take either finerenone or a placebo for 6 months. The main goal is to s…

This early-stage trial tests a new drug, BAY 3771249, that targets a specific cancer-driving mutation called KRAS G12D. It is for people with advanced or metastatic colorectal cancer who have this mutation and have tried other treatments. The drug is given alone or with another c…

This Phase 3 trial is testing a new oral drug, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 participants will be randomly assigned to receive either sevabertinib twice daily…

This phase 3 study tests whether finerenone, a drug that blocks inflammation and scarring in the heart, can improve heart function in children aged 6 months to 18 years with heart failure and left ventricular systolic dysfunction. About 111 participants will receive either finere…

This study tests darolutamide, a drug that blocks male hormones fueling prostate cancer, in Indian men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). All 50 participants will take darolutamide pills twice a day along with standard hormone therapy. Th…

This program offers oral sevabertinib to adults with advanced non-small cell lung cancer that has a specific HER2 gene change and has stopped responding to other treatments. Participants must have a life expectancy of at least 12 weeks and be in good enough health to take oral me…

This Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…

This study follows 500 men in Germany with metastatic hormone-sensitive prostate cancer (mHSPC) who are taking darolutamide plus standard hormone therapy. Researchers will check how many have very low PSA levels after 12 months and track survival and health over 5 years. The goal…

This early-stage study tests a new drug, 225Ac-PSMA-Trillium, in people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells to damage them. The main goals are to check safety, find the best …

This study looks at how well larotrectinib works and how safe it is for people with advanced or returning TRK fusion cancer. It includes both adults and children whose cancer has spread or come back. Researchers will collect information from medical records and doctor visits to s…

This observational study follows up to 2,000 adults with ATTR-CM, a serious heart condition, who are starting treatment with acoramidis as part of their normal care. Researchers will track patient characteristics, how the drug is used, and its effects on heart function and qualit…

This observational study in Germany looks at whether hydrotalcite (Talcid) can ease acid-related symptoms like heartburn that occur when people stop long-term use of proton pump inhibitors (PPIs). About 167 adults who recently stopped PPIs will take hydrotalcite as needed for fou…

This study is observing 200 adults scheduled for heart surgery to understand why some develop acute kidney injury afterward. Researchers will collect blood and urine samples before and after surgery to measure biomarkers linked to kidney damage. No experimental treatments are giv…

This study will follow 500 adults with chronic kidney disease and type 2 diabetes who are taking finerenone, a drug that helps protect the kidneys and heart. Researchers want to see if a tool called the Klinrisk score, which estimates the risk of kidney disease getting worse, imp…

This study looks at heart-related side effects in older men with advanced prostate cancer treated with enzalutamide or darolutamide. Researchers will analyze existing health records from 3,000 men aged 55 and older to compare rates of heart attacks, strokes, and heart-related dea…

This observational study will follow 100 Japanese men with low-volume metastatic hormone-sensitive prostate cancer who are receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will collect medical records to see how many men achieve very low PSA leve…

This observational study collects data from UK preterm babies with retinopathy of prematurity (ROP) who are treated with the drug aflibercept (Eylea) using a paediatric dosing device. The main goal is to count how many babies receive this treatment and decide if there are enough …

This study monitors the safety and effectiveness of darolutamide (Nubeqa) in 600 Korean men with non-metastatic or metastatic hormone-sensitive prostate cancer. Participants receive the drug as part of their normal care and are followed for one year. Researchers track side effect…

This study monitors the safety of Jivi (damoctocog alfa pegol) in 20 Korean patients with hemophilia A who have used other treatments before. Researchers will collect data from routine clinic visits over about 8 months per participant, looking for any medical problems. No extra t…

This study will analyze health records from 2009 to 2024 to find out how many people in Germany have three serious eye conditions: wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Researchers will look at data from two large German health …

This early-stage study tests whether a new drug (BAY3389934) for blood clotting problems in sepsis can be safely given with aspirin. Sixteen healthy adults will receive the drug alone, aspirin alone, and both together in random order. The goal is to check for side effects and see…

This observational study will follow 50,000 people in Asia and the United States who have chronic kidney disease and type 2 diabetes and are already taking finerenone as part of their regular care. Researchers will collect data from electronic health records and insurance claims …

This study analyzes anonymous prescription records from Australian databases to see how men with advanced prostate cancer are actually treated. Researchers will look at which drugs are used, patient ages, and how well people stick to their medication. The goal is to learn from re…

This study observes 1350 Korean adults with chronic heart failure who are prescribed Verquvo by their doctors. Researchers will track side effects and heart-related events over up to 12 months to see how safe and effective the drug is in everyday use. No experimental treatments a…

This study follows 300 people with Parkinson's disease who still have movement symptoms despite taking standard medications. Researchers will collect data over up to 5 years through questionnaires, diaries, medical records, blood samples, and a digital device. The goal is to bett…

This study is testing how reliable a kidney function test called renal functional reserve is. Researchers will give healthy people and those with kidney problems a protein shake, then take blood and urine samples to see how well their kidneys respond. The goal is to see if this t…

This study watches 500 adults in South Korea who have chronic kidney disease and type 2 diabetes and are taking finerenone as part of their normal care. Researchers will collect information from medical records and doctor visits over up to 12 months to see why doctors prescribe i…

This study follows 1,400 Japanese adults with chronic heart failure to see how safe the drug vericiguat is in everyday use. Half will take vericiguat plus standard care, the other half standard care alone. Researchers will track side effects, blood pressure, and heart-related dea…

This study follows 150 adults and children with advanced TRK fusion cancers who are already taking the drug larotrectinib (Vitrakvi). Researchers will collect data from routine doctor visits over 2 to 5 years to see how effective the drug is and what side effects occur. The goal …

This study is not testing a new drug but rather observing how darolutamide is actually used in everyday urology clinics for men with metastatic hormone-sensitive prostate cancer. Researchers will review medical records of about 1,400 patients to understand who gets which treatmen…

This study observes 300 adults in South Korea with chronic heart failure who are prescribed finerenone as part of their usual care. Researchers will track side effects and treatment satisfaction over one year. The goal is to see how safe and effective finerenone is in everyday me…